- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06281665
Behandeling met aspirine na pre-eclampsie: TAP-proef (TAP)
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Alisse K Hauspurg, MD
- Telefoonnummer: 412-641-1381
- E-mail: janickia@upmc.edu
Studie Contact Back-up
- Naam: Sila Yavan, MS
- Telefoonnummer: 4124174981
- E-mail: yavans@upmc.edu
Studie Locaties
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Werving
- University of Pittsburgh Magee-Womens Hospital
-
Contact:
- Sila Yavan, MS
- Telefoonnummer: 4124174981
- E-mail: yavans@upmc.edu
-
Hoofdonderzoeker:
- Alisse K Hauspurg, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Postpartum individuals ≥18 years old
- Preeclampsia diagnosis
Exclusion Criteria:
- Fetal anomaly
- Multiple gestation
- Pre-pregnancy hypertension
- Allergy or contraindication to low-dose aspirin
- Pre-pregnancy diabetes
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo Group
Similar appearing placebo pill daily for 6 months will be given to subjects. |
The control group will receive similar appearing placebo daily for 6 months. |
|
Experimenteel: Intervention Group
Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects |
The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent of participants eligible, enrolled and retained (feasibility)
Tijdsspanne: Baseline to approximately 6 months postpartum
|
To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia. |
Baseline to approximately 6 months postpartum
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Study visit systolic BP
Tijdsspanne: 2 months postpartum
|
Mean study visit systolic BP |
2 months postpartum
|
|
Study visit diastolic BP
Tijdsspanne: 2 months postpartum
|
Mean study visit diastolic BP |
2 months postpartum
|
|
Study visit systolic BP
Tijdsspanne: 6 months postpartum
|
Mean study visit systolic BP |
6 months postpartum
|
|
Study visit diastolic BP
Tijdsspanne: 6 months postpartum
|
Mean study visit diastolic BP |
6 months postpartum
|
|
Study visit mean arterial pressure
Tijdsspanne: 2 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
2 months postpartum
|
|
Study visit mean arterial pressure
Tijdsspanne: 6 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
6 months postpartum
|
|
Anti-hypertensive medication use
Tijdsspanne: 2 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
2 months postpartum
|
|
Anti-hypertensive medication use
Tijdsspanne: 6 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
6 months postpartum
|
|
Therapeutic intensity score
Tijdsspanne: 2 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
2 months postpartum
|
|
Therapeutic intensity score
Tijdsspanne: 6 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
6 months postpartum
|
|
Mean home systolic blood pressure
Tijdsspanne: delivery through 6 months postpartum
|
Mean home systolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home diastolic blood pressure
Tijdsspanne: delivery through 6 months postpartum
|
Mean home diastolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home mean arterial pressure
Tijdsspanne: delivery through 6 months postpartum
|
Mean home mean arterial pressure |
delivery through 6 months postpartum
|
|
Mean daytime systolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean daytime systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal systolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime diastolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal diastolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal mean arterial pressure
Tijdsspanne: 6 months postpartum
|
Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime mean arterial pressure
Tijdsspanne: 6 months postpartum
|
Mean daytime mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall mean arterial pressure
Tijdsspanne: 6 months postpartum
|
Mean overall mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall systolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean overall systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall diastolic blood pressure
Tijdsspanne: 6 months postpartum
|
Mean overall diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Classification of hypertension
Tijdsspanne: 2 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
2 months postpartum
|
|
Classification of hypertension
Tijdsspanne: 6 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
6 months postpartum
|
|
Endothelial function EC50%
Tijdsspanne: 2 months postpartum
|
EC50% from microiontophoresis |
2 months postpartum
|
|
Endothelial function EC50%
Tijdsspanne: 6 months postpartum
|
EC50% from microiontophoresis |
6 months postpartum
|
|
Endothelial function Emax
Tijdsspanne: 2 months postpartum
|
Emax from microiontophoresis |
2 months postpartum
|
|
Endothelial function Emax
Tijdsspanne: 6 months postpartum
|
Emax from microiontophoresis |
6 months postpartum
|
|
Endothelial function change in Emax
Tijdsspanne: 2 to 6 months postpartum
|
Change in Emax between visits |
2 to 6 months postpartum
|
|
Endothelial function change in EC50%
Tijdsspanne: 2 to 6 months postpartum
|
Change in EC50% between visits |
2 to 6 months postpartum
|
|
Change in systolic blood pressure
Tijdsspanne: 2 to 6 months postpartum
|
Change in study visit mean systolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in diastolic blood pressure
Tijdsspanne: 2 to 6 months postpartum
|
Change in study visit mean diastolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in mean arterial pressure
Tijdsspanne: 2 to 6 months postpartum
|
Change in study visit mean arterial pressure between visits |
2 to 6 months postpartum
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Infecties
- Eclampsie
- Pre-eclampsie
- Hypertensie, door zwangerschap veroorzaakt
- Hypertensie
- Hart-en vaatziekten
- Vaatziekten
- Zwangerschap Complicaties
- Toxemie
- Organische chemicaliën
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Koolwaterstoffen, aromatisch
- Fenolen
- Benzeenderivaten
- Salicyen
- Hydroxybenzoates
- Aspirine
Andere studie-ID-nummers
- STUDY23080099
- K23HL168356 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.
IPD-tijdsbestek voor delen
Within a year after outcomes are published and no later than 3 years after the end of clinical activities.
IPD-toegangscriteria voor delen
NHLBI data repository request process
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .